Toremifene in Treating Patients With Ovarian Cancer

Withdrawn before enrolling · Phase 2

Conditions studied: Ovarian Cancer

In brief

RATIONALE: Estrogen can stimulate the growth of ovarian cancer cells. Hormone therapy using toremifene may fight ovarian cancer by reducing the production of estrogen. PURPOSE: Randomized phase II trial to study the effectiveness of toremifene in treating patients who have recurrent or refractory ovarian cancer.

Key facts

Study ID

NCT00003865

Run by

George Washington University

People needed

0

Starts

1999-07-22

Expected to finish

2017-02-22

Last updated by the study team

2017-07-13

Who can join

Age: 18 and older, up to 120. Sex: female. Healthy volunteers: not accepted.

Where it is running

• George Washington University Cancer Center — Washington D.C., District of Columbia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.